Celltrion Initiates P-III Study of CT-P42 (biosimilar, aflibercept)

 Celltrion Initiates P-III Study of CT-P42 (biosimilar, aflibercept)

Celltrion Initiates P-III Study of CT-P42 (biosimilar, aflibercept)

Shots:

  • Celltrion has launched a global P-III clinical trial of CT-P42 which is an investigational biosimilar candidate referencing Regeneron’s Eylea (aflibercept)
  • The study will enroll 300 patients with DME and aims to compare CT-P42’s efficacy, safety, pharmacokinetics, and immunogenicity against Eylea
  • Celltrion adds CT-P42 to its pipeline of other investigational biosimilars, including CT-P17 (referencing Humira), CT-P16 (referencing Avastin), CT-P39 (referencing Xolair), CT-P41 (referencing Prolia), and CT-P43

Click here ­to­ read full press release/ article | Ref: Pulse  | Image: Celltrion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post